Isabel Chirivella

2.6k total citations · 1 hit paper
53 papers, 1.5k citations indexed

About

Isabel Chirivella is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Isabel Chirivella has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 17 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Isabel Chirivella's work include BRCA gene mutations in cancer (9 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Treatment and Pharmacology (9 papers). Isabel Chirivella is often cited by papers focused on BRCA gene mutations in cancer (9 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Treatment and Pharmacology (9 papers). Isabel Chirivella collaborates with scholars based in Spain, France and United States. Isabel Chirivella's co-authors include Andrés Cervantes, Gérard Lledo, Thierry André, Arié Figer, M. Flesch, Élisabeth Carola, Fernando Rivera, Christophe Tournigand, Laurent Mineur and Nathalie Perez‐Staub and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Isabel Chirivella

49 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

2006 583 citations Andrés Cervantes, Isabel Chirivella et al. profile →

Peers

Isabel Chirivella

ONCOL

PRM

HEPAT

Allyson J. Ocean United States

Thomas Makatsoris Greece

K. Haider Austria

Daniela Kandioler Austria

David Rinaldi United States

B. Mirtsching United States

Eugenio Marcuello Spain

Carles Pericay Spain

L Herrera United States

A. Antón Spain

Allyson J. Ocean United States

Isabel Chirivella

1.1k ×1.0

ONCOL

496 ×1.1

PRM

335 ×1.3

HEPAT

205 ×0.8

477 ×1.9

Citations per year, relative to Isabel Chirivella Isabel Chirivella (= 1×) peers Allyson J. Ocean

Countries citing papers authored by Isabel Chirivella

Since Specialization

Citations

This map shows the geographic impact of Isabel Chirivella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Chirivella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Chirivella more than expected).

Fields of papers citing papers by Isabel Chirivella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Chirivella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Chirivella. The network helps show where Isabel Chirivella may publish in the future.

Co-authorship network of co-authors of Isabel Chirivella

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Chirivella. A scholar is included among the top collaborators of Isabel Chirivella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Chirivella. Isabel Chirivella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Puente, Javier, Alejo Rodríguez‐Vida, Elena Sevillano, et al.. (2025). SEOM–SOGUG clinical guideline for urothelial cancer (2025). Clinical & Translational Oncology. 27(11). 4142–4159.

Cajal, Teresa Ramón y, Marta Pineda, Elena Aguirre, et al.. (2023). SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 25(9). 2627–2633. 4 indexed citations

Jiménez, Natàlia, Òscar Reig, Mercedes Marín‐Aguilera, et al.. (2022). Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. Cancers. 14(19). 4757–4757. 8 indexed citations

Liello, Raimondo Di, Begoña Bermejo, Cristina Hernándo, et al.. (2021). Fertility and breast cancer: A literature review of counseling, preservation options and outcomes. Critical Reviews in Oncology/Hematology. 166. 103461–103461. 15 indexed citations

Tena, Isabel, et al.. (2021). Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families. Journal of Personalized Medicine. 11(6). 548–548. 5 indexed citations

Oltra, Sara S., Juan Miguel Cejalvo, Eduardo Tormo, et al.. (2020). HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Cancers. 12(2). 412–412. 14 indexed citations

Lázaro-Quintela, Martín, Begoña P. Valderrama, Cristina Suárez, et al.. (2020). SEOM clinical guideline for treatment of kidney cancer (2019). Clinical & Translational Oncology. 22(2). 256–269. 17 indexed citations

Reynés, Gaspar, Luisa Sánchez‐Lorenzo, Emilio Esteban, et al.. (2019). Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. Cancer Chemotherapy and Pharmacology. 84(4). 781–789. 2 indexed citations

García‐Casado, Zaida, Antonio Fernández‐Serra, Sarai Palanca, et al.. (2019). Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS). Hereditary Cancer in Clinical Practice. 17(1). 3–3. 11 indexed citations

10.

Méndez-Vidal, María José, Urbano Anido, Isabel Chirivella, et al.. (2018). Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacology and Toxicology. 19(1). 77–77. 20 indexed citations

11.

Guillén‐Ponce, Carmen, Rafael Serrano del Rosal, Àlex Teulé, et al.. (2015). Clinical guideline seom: hereditary colorectal cancer. Clinical & Translational Oncology. 17(12). 962–971. 10 indexed citations

12.

Llort, Gemma, Isabel Chirivella, Rafael Morales, et al.. (2015). SEOM clinical guidelines in Hereditary Breast and ovarian cancer. Clinical & Translational Oncology. 17(12). 956–961. 81 indexed citations

13.

Martínez, María Teresa, Isabel González‐Álvarez, Noelia Tarazona, et al.. (2014). Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment. Clinical & Translational Oncology. 17(2). 167–172. 8 indexed citations

14.

Palanca, Sarai, Eva Barragán, Isabel Chirivella, et al.. (2012). The deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families. Familial Cancer. 12(1). 119–123. 8 indexed citations

15.

Baselga, José, Andrés Cervantes, Erika Martinelli, et al.. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research. 16(19). 4876–4883. 95 indexed citations

16.

Fidalgo, José Alejandro Pérez, Susana Roselló, Elisa García-Garré, et al.. (2009). Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Research and Treatment. 120(1). 245–251. 50 indexed citations

17.

Fidalgo, José Alejandro Pérez, Isabel Chirivella, Josefa Ibáñez, et al.. (2008). Impact of mammography screening programme in the breast cancer population of the Region of Valencia (Spain). Clinical & Translational Oncology. 10(11). 745–752. 7 indexed citations

18.

Chirivella, Isabel, et al.. (2008). Coexistencia de dos tumores germinales seminomatoso y no seminomatoso con una presentación clínica inhabitual. Archivos Españoles de Urología. 61(5). 626–30. 2 indexed citations

19.

Cervantes, Andrés, et al.. (2006). A multimodality approach to localized rectal cancer. Annals of Oncology. 17. x129–x134. 11 indexed citations

20.

Maurel, Joan, Andrés Cervantes, C. Conill, et al.. (2005). Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. International Journal of Radiation Oncology*Biology*Physics. 62(1). 91–96. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact